Navigation Links
CV Therapeutics to Announce 2008 Second Quarter Financial Results on Thursday, July 31, 2008
Date:7/22/2008

te exercise stress. Ranolazine is approved for use in the European Union as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies.


'/>"/>
SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...r 6 EUCODIS Bioscience, a company,...ing enzymes for the,chemical industry announced to...with Bio Sidus, the leading biopharmaceutical comp...es EUCODIS Bioscience exclusive access - for the s...ietary collection of,psychrophilic bacteria strain...
(Date:11/6/2009)...da for Arrowhead’s 2010 Personalized Medicin...ace on February 22-24, 2010 in Philadelphia, has b...l highlight key issues in forming partnerships and...es. , Minneapolis, MN (PR...rsquo;s 2010 Personalized Medicine Partnerships C...
(Date:11/5/2009)...e-FirstCall/ -- Imagenetix, Inc. (OTC Bulletin Boa...resident and CEO of Imagenetix, will be presenting...nference on Thursday, December 3rd, at 10:30 AM PS...D MICRO ,, LD MICRO is a by-invitation only new...ompanies in the micro-cap space. Since 2002, the f...
(Date:11/5/2009)...RNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD ) t...g at the following investor conferences, and invit... Credit Suisse Healthcare Conference, Ph...2009 at 10 a.m. Mountain Time, NA... Tuesday, 1 December, 2009 at 10.45 ...
Breaking Biology Technology:EUCODIS Bioscience to Explore Novel Enzymatic Activities in Antarctic Bacteria Library From Bio Sidus 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 3Imagenetix to Present at 2nd Annual LD MICRO Conference at the Luxe Sunset Bel Air 2Cepheid to Webcast Upcoming Financial Presentations 2
...2 Nektar,Therapeutics (Nasdaq: NKTR ) announced ...nsition from a drug delivery service provider to a...estructuring will,streamline the company, consolid...aking and execution within the business units., "... development company,and these changes are a natur...
...formance in 2007 and Notes Achievements over 4-ye... BioSciences, Preparing for Cha...ing-Plough,Corporation (NYSE: SGP ) today reporte...d full year, and commented on its ongoing integrat...cquired in November 2007 and,includes the Organon ...
...nternational,Corporation (Nasdaq: PRXL ) announce... 2-for-1 split of its Common Stock, which will be ...ers of PAREXEL,s Common Stock will receive one add...mmon Stock held on the record date of,February 22,...n or about,March 3, 2008 by PAREXEL,s transfer age...
Other Biology Technology:Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization 2Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization 3Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 2Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 3Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 4Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 5Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 6Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 7Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 8Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 9Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 10Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 11Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 12Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 13Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 14Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 15Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 16Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 17Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 18Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 19Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 20Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 21Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 22Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 23Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 24Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 25Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 26Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 27Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 28PAREXEL International Announces 2-For-1 Stock Split 2PAREXEL International Announces 2-For-1 Stock Split 3
(Date:11/4/2009)... 2009 Childhood obesity in the United States is r...ourth of advertising on daytime and prime time tel...ing questions about the role television plays in o...the Journal of Nutrition Education and Behavior ...ght be a large contributor to the problem. , Res...
(Date:11/4/2009)...hat deciphered the DNA codes, or genomes, of the f...joined The Genome 10K Project, an international ef...ences on 10,000 species of animals for conducting ...not be achieved. , Participating in The Genome 1...Nov. 5, 2009 issue of the Journal of Heredity , a...
(Date:11/4/2009)..., Oct. 19 Spectros, developer and ...ging devices which shed light on life-threatening ...sive distribution deals for both its T-Stat® ...red include Australia, New Zealand, The Netherlan..., France, Spain, Portugal, Poland, Greece, Turkey,...
Breaking Biology News(10 mins):TV bombards children with commercials for high-fat and high-sugar foods 2TV bombards children with commercials for high-fat and high-sugar foods 3Singapore scientists join international study of 10,000 vertebrates' genomes 2Spectros Signs New International Distribution Deals 2Donor Sperm Providers Form New Non Profit 59569 1Oaks Development Group Launches Physician Incubator Space in Palm Coast Medical Office Building 59566 1Oaks Development Group Launches Physician Incubator Space in Palm Coast Medical Office Building 59566 2MedImmune Highlights Inflammatory Disease Portfolio at 73rd Annual Meeting of the American College of Rheumatology 14494 1MedImmune Highlights Inflammatory Disease Portfolio at 73rd Annual Meeting of the American College of Rheumatology 14494 2MedImmune Highlights Inflammatory Disease Portfolio at 73rd Annual Meeting of the American College of Rheumatology 14494 3
...reasing amounts of ice mass have been lost from We... past ten years, according to research from the Un... in Nature Geoscience. , Meanwhile the ice mass ...either loss nor accumulation over the past decade.... Bristol and colleagues estimated the flux of ice ...
...N ARBOR, Mich.---Common genetic variants linked to... new study shows. , The international study was c...ic Health. The journal Nature Genetics will publis...onfirms observations by health professionals of a ...risk of osteoarthritis, the most common form of ar...
...tudies involving more than 35,000 people and a sur...al team supported in part by the National Institut...genetic variants recently linked to osteoarthritis...indings were released today in the advance online ...e variants most strongly associated with height in...
Other Biology News:Antarctic ice loss 2Study suggests genetic connection between short stature and arthritis 2Researchers uncover new piece to the puzzle of human height 2Researchers uncover new piece to the puzzle of human height 3Researchers uncover new piece to the puzzle of human height 4
Duck Anti-Cobra venom - Fab Fragment Polyclonal Antibody, Unconjugated from Abcam
Fetuin from Equitech-Bio
Mouse Anti-JNK, phospho (Thr183 / Thr185) Antibody, Unconjugated from Raybiotech, Inc.
Anti-Acetyl CoA Carboxylase Antibody, Unconjugated from Cell Signaling Technology
Biology Products: